Not always a good night's sleep: A global pharmacovigilance risk profiling of drug-induced sleep disorders
Sleep Medicine · 2026-11 · 147 · 109161
DOI: 10.1016/j.sleep.2026.109161 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sleep Medicine, 2026-11. Verfasst von Mohan Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: The School of Pharmacy, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Sleep Wake Disorders, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Fujian Provincial Health Commission, Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
OBJECTIVES Sleep disorders and disturbances affect more than one-third of the global population. Although certain drugs have been implicated, the real-world breadth and strength of these signals across therapeutic classes remain poorly characterised. This study aimed to systematically profile drug-induced sleep disorders and disturbances using large-scale pharmacovigilance data and to identify drugs with disproportionate reporting, including those not previously well recognised. METHODS We analyzed 21 years of post-marketing surveillance data using four disproportionality algorithms (Reporting Odds Ratio [ROR], Proportional Reporting Ratio [PRR] with χ2, Bayesian Confidence Propagation Neural Network [BCPNN], and Multi-item Gamma Poisson Shrinker [MGPS]), leveraging their complementary strengths in sensitivity, bias reduction, stability, and rare-event detection. Positive signals were defined as meeting pre-specified thresholds for all four algorithms simultaneously. RESULTS Among over 22 million reports, 411,736 involved sleep disorders (58.9% female). Overall, 131 drugs showed disproportionate signals; 24 (18.3%) lacked FDA-labelled warnings. Varenicline accounted for the most reports (n = 16,200), whereas montelukast showed the strongest signal (ROR 11.78, 95% CI 11.40-12.18). Median time to onset was 36 days (IQR: 6-260), with an early failure-type profile (Weibull β = 0.449, 95% CI 0.447-0.452). Among therapeutic classes, antineoplastic and immunomodulating agents (ATC L01) showed the highest disproportionality (ROR 9.19, 95% CI 8.86-9.53). CONCLUSIONS Multiple drug classes show disproportionate reporting for sleep disorders and disturbances with an early-onset risk profile, supporting monitoring at treatment initiation. Approximately one in five of these drugs lack US labelling warnings, highlighting the need for clinical awareness and mechanistic studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The School of Pharmacy, Fujian Medical University, Fuzhou, China.
- School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
- Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.
- The Third Department of Critical Care Medicine, Fuzhou University Affiliated Provincial Hospital, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, Fujian, China.
- Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University, Fuzhou, China. Electronic address: summerjuling@126.com.
Förderung
- Fujian Provincial Health Commission
- Natural Science Foundation of Fujian Province
Zitieren
APA
Zhang, M., Li, J., Huang, S., You, H., Li, W., Gong, S., & Wang, L. (2026). Not always a good night's sleep: A global pharmacovigilance risk profiling of drug-induced sleep disorders. Sleep Medicine, 147, 109161. https://doi.org/10.1016/j.sleep.2026.109161
Vancouver
Zhang M, Li J, Huang S, You H, Li W, Gong S, et al. Not always a good night's sleep: A global pharmacovigilance risk profiling of drug-induced sleep disorders. Sleep Medicine. 2026;147:109161. doi:10.1016/j.sleep.2026.109161
BibTeX
@article{Zhang2026,
author = {Zhang, Mohan and Li, Jinglin and Huang, Shasha and You, Hongyuan and Li, Wen and Gong, Shurong and Wang, Ling},
title = {Not always a good night's sleep: A global pharmacovigilance risk profiling of drug-induced sleep disorders},
journal = {Sleep Medicine},
year = {2026},
volume = {147},
pages = {109161},
doi = {10.1016/j.sleep.2026.109161}
}
EUVIMED